Les Newsletters de Stop-Tabac.ch
25 février 2014
- E-cigarette : le ni oui ni non de la Haute Autorité de santé
- Le marché des patchs sous pression face au succès de l'e-cigarette
- Le marché discret de l'e-cigarette en Suisse
- Why Philip Morris International's New Heated Products Will Do Better Than Its Last Attempt
- Change in mental health after smoking cessation: systematic review and meta-analysis
- Chattez avec un médecin tabacologue
Le Monde - Quels sont les moyens pour arrêter de fumer ? Les recommandations de la Haute Autorité de santé (HAS), rendues publiques mardi 21 janvier, étaient attendues, notamment sur la cigarette électronique. Sans surprise, elle n'a pas tranché. La cigarette électronique n'est pas recommandée à ce jour mais son utilisation n'est pas découragée , avance prudemment la HAS. Lire la suite:...
Les substituts nicotiniques accusent une baisse de leurs ventes, selon certains fabricants. Les acteurs de l''e-cigarette se défendent de les concurrencer.. Lire la suite;...
L'AGEFI, 19.02.2014 - Plusieurs petites sociétés ont été créées depuis l'an dernier. Les entreprises transnationales ne s'intéressent pas encore au marché national. Article en PDF:
http://www.unige.ch/presse/static/revue-de-presse/articles/AGEFI_190214_cigarette.pdf (19 02 2014)
(25 02 2014)
Philip Morris International (NYSE: PM ) is coming out with new heated tobacco products that may provide a much-needed source of growth amid declining cigarette sales. Altria Group (NYSE: MO ) licensed the products for distribution in the United States. However, Philip Morris has released heated products before, so investors are not sure if the new products will be a game-changer or another flop. Read more...:
http://www.fool.com/investing/general/2014/02/01/why-philip-morris-internationals-new-heated-produc.aspx (19 02 2014)
(25 02 2014)
Objective To investigate change in mental health after smoking cessation compared with continuing to smoke.
Design Systematic review and meta-analysis of observational studies.
Data sources Web of Science, Cochrane Central Register of Controlled Trials, Medline, Embase, and PsycINFO for relevant studies from inception to April 2012. Reference lists of included studies were hand searched, and authors were contacted when insufficient data were reported.
Eligibility criteria for selecting studies Longitudinal studies of adults that assessed mental health before smoking cessation and at least six weeks after cessation or baseline in healthy and clinical populations.
Results 26 studies that assessed mental health with questionnaires designed to measure anxiety, depression, mixed anxiety and depression, psychological quality of life, positive affect, and stress were included. Follow-up mental health scores were measured between seven weeks and nine years after baseline. Anxiety, depression, mixed anxiety and depression, and stress significantly decreased between baseline and follow-up in quitters compared with continuing smokers: the standardised mean differences (95% confidence intervals) were anxiety ?0.37 (95% confidence interval ?0.70 to ?0.03); depression ?0.25 (?0.37 to ?0.12); mixed anxiety and depression ?0.31 (?0.47 to ?0.14); stress ?0.27 (?0.40 to ?0.13). Both psychological quality of life and positive affect significantly increased between baseline and follow-up in quitters compared with continuing smokers 0.22 (0.09 to 0.36) and 0.40 (0.09 to 0.71), respectively). There was no evidence that the effect size differed between the general population and populations with physical or psychiatric disorders.
Conclusions Smoking cessation is associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke. The effect size seems as large for those with psychiatric disorders as those without. The effect sizes are equal or larger than those of antidepressant treatment for mood and anxiety disorders.
BMJ 2014;348:g1151 (Published 13 February 2014)
Gemma Taylor, Ann McNeill, Alan Girling, Amanda Farley, Nicola Lindson-Hawley, Paul Aveyard
http://www.bmj.com/content/348/bmj.g1151.pdf%2Bhtml (14 02 2014)
(25 02 2014)